Should You Microdose Ketamine? A Physician's Honest Answer

Microdosing became a cultural moment over the past few years, mostly driven by stories about psilocybin and LSD for productivity and mood. Patients started asking me about microdosing ketamine: taking tiny, sub-perceptual doses on a regular schedule rather than full therapeutic doses in structured sessions. It's a reasonable question and I want to give it a real answer rather than a marketing one.

The short version: there isn't clinical evidence to support microdosing ketamine for depression. The longer version requires defining what microdosing actually means, looking at what's known versus assumed, and (often the more useful part) figuring out what the patient is actually worried about when they ask.

Getting the terms right

The word "microdose" gets used loosely. Before we can compare, let me lay out what each dosing strategy actually looks like.

Microdose is a fraction of a standard therapeutic dose (usually around one-tenth to one-twentieth) taken on a regular schedule, often daily or every few days. The defining feature is that it's sub-perceptual: you don't feel dissociation, don't notice altered perception, don't experience a distinct session. The theoretical appeal is that you'd get cumulative neurochemical benefits without the acute psychoactive experience.

Full therapeutic dose is what the clinical evidence base is built on and what we use at Tovani Health. At this dose, you experience dissociation, altered perception, and a distinct 45- to 90-minute session followed by a recovery period. The session is an event, not a tablet you swallow with breakfast.

Sub-therapeutic perceptible doses occupy a middle ground: enough to feel something subtle, not enough for a full session experience. Some providers use this range. The evidence base for it is weaker than either extreme.

What the evidence actually shows

For full therapeutic doses, the evidence is robust. The landmark studies that established ketamine as a rapid-acting antidepressant used IV doses of 0.5 mg/kg, a dose that reliably produces dissociation. Subsequent research using sublingual, intramuscular, and intranasal routes has used equivalent dosing that produces comparable effects. Multiple randomized controlled trials, meta-analyses, and real-world clinical studies consistently find that full-dose ketamine produces response rates of 60-70% in treatment-resistant depression, rapid onset (hours to days), and measurable neuroplasticity changes on brain imaging.

For microdosing, the evidence is thin. There are no large, randomized, controlled trials demonstrating that sub-perceptual ketamine doses produce meaningful antidepressant effects in humans. What exists is:

Preclinical animal studies showing behavioral changes at low doses in rodent models. These are hypothesis-generating at best; rodent dose-response in depression models translates poorly to humans.

Anecdotal reports from patients and some providers claiming benefit. Anecdote is useful for identifying questions worth studying but can't establish efficacy. Placebo effects, expectation, and natural symptom fluctuation are powerful confounders that anecdote can't separate from a real drug effect.

Small, uncontrolled case series with mixed results and methodological limitations.

This doesn't mean microdosing definitively doesn't work. It means we don't yet have the evidence to say whether it works, how well, or for whom. The distinction between "unproven" and "disproven" matters in medicine: the honest statement is "we don't know yet," not "it's been shown to fail."

Why the experience may be part of the therapy, not a side effect

One of the active questions in ketamine research is whether the dissociative experience itself is therapeutically relevant or whether it's just the side effect of a dose high enough to trigger the underlying neurochemistry. The emerging answer is that the experience probably matters.

There are a few reasons to think so.

During a full-dose session, patients often gain new perspectives on their depression, relationships, or life patterns. The shift in perspective (sometimes described as seeing your situation from outside yourself) can catalyze change in a way that a daily pill can't. Sub-perceptual doses, by definition, don't produce this.

The dissociative state temporarily interrupts the repetitive ruminative thought patterns that characterize depression. That interruption may be doing therapeutic work, allowing new patterns to consolidate during the plasticity window. There's no comparable interruption at microdoses.

Studies that compare different doses within the therapeutic range find a dose-response relationship: higher doses (within safe range) produce stronger antidepressant effects. That's a strong clue that the neurobiological cascade ketamine triggers is dose-dependent. Below some threshold, it may not engage at all.

Brain imaging shows that full-dose ketamine significantly alters activity in the default mode network (the brain system tied to self-referential rumination). Whether microdoses meaningfully affect the DMN is unknown; there's no comparable published data.

The mechanism question, simply

The core therapeutic action of ketamine involves NMDA receptor blockade triggering a glutamate cascade, BDNF release, and synaptogenesis (new synaptic connections forming). This sequence has been clearly demonstrated at full therapeutic doses in both animal and human research.

The mechanistic question for microdosing is whether sub-perceptual doses produce enough NMDA receptor occupancy to initiate the cascade at all. The blockade that triggers the downstream effects requires a threshold of receptor binding. Below that threshold, the reaction may not start.

A useful analogy: a match needs enough friction to ignite. You can drag a match slowly across a surface all day and never generate enough heat to produce a flame. The same principle may apply here. That's not proven, but it's the simpler explanation given the evidence, and it's the one I'd start with before paying for a less-studied protocol.

What patients are usually really asking

When someone asks me about microdosing, they're often worried about something more specific than dosing philosophy. Let me address the concerns I hear most.

"I'm afraid of the dissociative experience." This is the most common worry, and it's fair. The idea of an altered state of consciousness is unfamiliar and can feel threatening. In practice, most patients find the experience less frightening than they anticipated. The dissociation is gentle, time-limited, and occurs in the safety of your own home with a sitter present. Many patients end up describing the sessions as a valued part of treatment, a quiet space they get to have.

"I don't want to be impaired." Full-dose ketamine does involve temporary impairment and a few hours of activity restrictions on dose days. But this is time-limited. Between sessions there's no daily impairment because there's no daily medication. Microdosing's appeal (no noticeable effects) comes with the substantial trade-off of no proven efficacy. You'd be taking something daily that we're not confident does anything.

"I want something I can take every day without disruption." If daily oral medication is what fits your life, there are evidence-based daily antidepressants worth considering: SSRIs, SNRIs, Wellbutrin. Ketamine therapy is a different model: periodic intensive sessions rather than daily maintenance. Its strength lies in that structure, not in spite of it.

"I read online that microdosing works." Online testimonials and wellness influencer content can be persuasive, but they're not the same as clinical evidence. The economics of wellness content favor confident, positive claims whether or not the underlying research supports them. If you bring a claim you read online into an evaluation, I'm happy to look at the source material with you.

The future might change this answer

Research evolves. It's entirely possible that rigorous clinical trials will eventually demonstrate effective microdosing protocols for ketamine, and if they do, clinical practice should change. Current practice should be guided by current evidence, and current evidence supports full therapeutic dosing.

If you're considering ketamine therapy and the dose question is what's holding you back, a real conversation in evaluation is often the most useful next step. Some concerns I can address with information; some patients need to work through their relationship to the dissociative experience, which is a normal part of preparation.

Frequently Asked Questions

Does ketamine microdosing actually work for depression?

The honest answer: there's no published clinical evidence that microdosing ketamine produces the antidepressant effects that full doses produce. All major trials demonstrating ketamine's 60-70% response rate in treatment-resistant depression use therapeutic doses that produce perceptible dissociative effects (typically 0.5 mg/kg IV or sublingual equivalent). Daily microdosing protocols (e.g., 25-50 mg sublingual nightly) are popular in some commercial programs but lack the rigorous comparative data that would justify recommending them clinically.

Why might the dissociative experience be necessary to ketamine's effect?

Several lines of evidence suggest the dissociative state may be part of the therapeutic mechanism, not just a side effect. The synaptic plasticity, BDNF release, and AMPA-receptor activation that produce ketamine's antidepressant effect appear to require enough receptor occupancy to produce noticeable subjective effects. Patients who have a perceptible dissociative experience tend to respond better than those who don't (correlation, not yet proven causation). The "set and setting" framework from psychedelic therapy also suggests the experience itself, when integrated, contributes to durable change.

What about Joyous-style daily microdosing?

Joyous and similar daily-microdosing services use lower oral ketamine doses taken daily rather than higher doses in structured sessions. The model has appeal: less intense, more habitual, lower per-dose cost. The challenge is that it lacks the published efficacy data that supports the structured-session model used in trials. Some patients report subjective benefit; whether that's specific to ketamine's antidepressant mechanism or attributable to expectation and sub-perceptual sedative effects is unclear. Most physicians would suggest doing a structured course first to establish whether ketamine works for you before considering a daily-low-dose maintenance approach.

I want to avoid the dissociative experience, what are my options?

Tell your physician what specifically concerns you. Many patients fear "losing control"; at therapeutic at-home doses (10-25% of anesthetic doses) actual loss of control is rare and the experience is usually closer to a deep meditative state than a "trip." Anti-nausea support, anxiolytic premedication for first-session anxiety (carefully chosen so it doesn't blunt response), and starting at the lower end of the therapeutic range are all options. Some patients who initially want to microdose end up doing fine with a standard sublingual protocol once they understand what the experience actually is.

Ready to find out if at-home ketamine fits your situation?

If the dose question is what's holding you back, here's the entry point. The evaluation is thorough and the answer is honest.

• Eligibility check: tovanihealth.com/eligibility (5 minutes, FL and NJ residents)
• Phone: 561-468-6981
• What you get back: an honest answer about whether at-home ketamine at a therapeutic dose is a reasonable fit, including referral elsewhere if it's not.

Benjamin Soffer, DO — Tovani Health

Related reading: what the experience feels like, safety protocols, side effects and risks, treatment-resistant depression.